GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » PB Ratio

ALPMF (Astellas Pharma) PB Ratio : 1.74 (As of Apr. 05, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-05), Astellas Pharma's share price is $9.45. Astellas Pharma's Book Value per Share for the quarter that ended in Dec. 2024 was $5.43. Hence, Astellas Pharma's PB Ratio of today is 1.74.

Good Sign:

Astellas Pharma Inc stock PB Ratio (=1.77) is close to 10-year low of 1.66.

The historical rank and industry rank for Astellas Pharma's PB Ratio or its related term are showing as below:

ALPMF' s PB Ratio Range Over the Past 10 Years
Min: 1.66   Med: 2.4   Max: 3.25
Current: 1.67

During the past 13 years, Astellas Pharma's highest PB Ratio was 3.25. The lowest was 1.66. And the median was 2.40.

ALPMF's PB Ratio is ranked better than
56.02% of 939 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs ALPMF: 1.67

During the past 12 months, Astellas Pharma's average Book Value Per Share Growth Rate was -0.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 6.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 6.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Astellas Pharma was 10.90% per year. The lowest was 1.10% per year. And the median was 4.25% per year.

Back to Basics: PB Ratio


Astellas Pharma PB Ratio Historical Data

The historical data trend for Astellas Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma PB Ratio Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 2.25 2.30 2.27 1.88

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 1.88 1.59 1.87 1.82

Competitive Comparison of Astellas Pharma's PB Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's PB Ratio falls into.


;
;

Astellas Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Astellas Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=9.45/5.425
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Astellas Pharma  (OTCPK:ALPMF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Astellas Pharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.